(Sannino et al. 2018; Wang, Wang, et al. 2018) demonstrated that 4‐hydroxybenzoic acid could be applied as an effective inhibitor of histone deacetylase 6 (HDAC6) to reverse resistance to treatment in human breast cancer. Here, HDAC6 is linked to breast carcinoma.